Valuation: MapLight Therapeutics, Inc.

Market Cap 535M 475M 445M 405M 763M 51.53B 773M 5.38B 2.08B 26.24B 2.01B 1.97B 84.29B P/E 2026 *
-1.95x
P/E 2027 * -2.52x
Enterprise Value 216M 192M 180M 164M 308M 20.83B 313M 2.17B 842M 10.61B 812M 795M 34.08B EV / Sales 2026 *
-
EV / Sales 2027 * 11.1x
Free-Float
47.72%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: MapLight Therapeutics, Inc.

1 day+1.30%
1 week-7.27%
Current month-4.81%
1 month-25.73%
3 months-73.85%
6 months-54.18%
Current year-44.78%
1 week 9.43
Extreme 9.43
10.64
1 month 9.43
Extreme 9.43
14.22
Current year 9.1
Extreme 9.1
40.43
1 year 9.1
Extreme 9.1
40.43
3 years 9.1
Extreme 9.1
40.43
5 years 9.1
Extreme 9.1
40.43
10 years 9.1
Extreme 9.1
40.43
Manager TitleAgeSince
Chief Executive Officer 58 2018-10-31
Director of Finance/CFO 45 2026-06-17
Chief Tech/Sci/R&D Officer 70 2019-01-31
Director TitleAgeSince
Director/Board Member 58 2018-10-31
Chairman 65 2024-04-30
Director/Board Member 65 2023-07-23
Date Insider Type Main position Quantity % Market Cap. Importance
9/16/26 Sell

General Counsel

-16,509 0.0312%
8/17/26 Free

Founder

117,100 0.2216%
8/17/26 Free

Chief Technology Officer

39,125 0.0740%
Change 5-day change 1-year change 3-year change Capi.($)
+1.30%-7.27% - - 535M
+4.16%+3.04%+49.37%+94.17% 74.41B
-2.76%-3.10%+22.46%+75.37% 59.26B
+1.03%-0.67%+4.24%+34.46% 47.14B
-0.40%-4.11%+26.87%+33.72% 42.91B
+0.00%+1.00%+353.00%+691.06% 44.13B
-1.66%-1.71%+2.76%+98.70% 40.79B
+3.32%+3.49%+10.10%+51.23% 30.77B
-2.68%+2.92%+29.63%+22.72% 29.31B
-0.15%-8.00%-29.05%+327.30% 23.71B
Average +0.25%-1.52%+52.15%+158.75% 39.3B
Weighted average by Cap. +0.37%-0.33%+57.43%+150.52%

Financials

2026 *2027 *
Net sales - 16.67M 14.8M 13.84M 12.62M 23.75M 1.6B 24.08M 167M 64.83M 817M 62.58M 61.22M 2.62B
Net income -244M -217M -203M -185M -348M -23.5B -353M -2.45B -949M -11.97B -916M -896M -38.44B -236M -210M -196M -179M -337M -22.74B -341M -2.37B -919M -11.58B -887M -868M -37.2B
Net Debt -319M -283M -265M -241M -454M -30.69B -461M -3.2B -1.24B -15.63B -1.2B -1.17B -50.21B -350M -311M -291M -265M -499M -33.71B -506M -3.52B -1.36B -17.17B -1.31B -1.29B -55.15B
Logo MapLight Therapeutics, Inc.
MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on improving the lives of patients suffering from debilitating central nervous system disorders (CNS). Its lead product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist, ML-007, co-formulated with a peripherally acting anticholinergic (PAC), which it is initially developing for the treatment of schizophrenia and Alzheimer’s disease psychosis (ADP). ML-007C-MA is designed to activate both M1 and M4 muscarinic receptors in the CNS to drive efficacy, while synchronizing the pharmacokinetics of the agonist and antagonist components to mitigate peripheral cholinergic side effects. Its second product candidate, ML-004, is a 5-HT1B/1D agonist that the Company is developing for the treatment of social communication deficit and/or irritability in autism spectrum disorder. It is also advancing two preclinical programs, ML-021 and ML-009.
Employees
133
Date Price Change Volume
26-10-02 US$9.710 +0.83% 25,407
26-10-01 US$9.630 -5.50% 432,225
26-09-30 US$10.19 +0.39% 303,256
26-09-29 US$10.15 -2.87% 408,312
26-09-28 US$10.45 -0.10% 251,569
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
9.630USD
Average target price
26.54USD
Spread / Average Target
+175.58%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MPLT Stock